Table 2. Immune-related adverse events reported in clinical trials of ICIs in relapsed TETs.

Immune-related adverse event	NCT02364076 (Pembrolizumab)		NCT02607631 (Pembrolizumab)			NCT01772004 (Avelumab)
	Thymic carcinoma		Thymoma	Thymic carcinoma		Thymoma
Number of patients	40		7	26		7
irAE, n [%]
Myasthenia gravis	1 [3]		1 [14]	2 [8]		0 [0]
Myocarditis	2 [5]		3 [43]	0 [0]		4 [57]
Polymyositis	3 [8]		0 [0]	0 [0]		4 [57]
Hepatitis	5 [13]		2 [29]	2 [8]		4 [57]
Pancreatitis	1 [3]		0 [0]	0 [0]		0 [0]
Bullous pemphigoid	1 [3]		0 [0]	0 [0]		0 [0]
Thyroiditis	0 [0]		1 [14]	1 [4]		0 [0]
Colitis	0 [0]		1 [14]	0 [0]		0 [0]
Nephritis	0 [0]		1 [14]	0 [0]		0 [0]
Conjunctivitis	0 [0]		1 [14]	0 [0]		0 [0]
Subacute myoclonus	0 [0]		0 [0]	1 [4]		0 [0]
Enteritis	0 [0]		0 [0]	0 [0]		1 [14]
Cranial neuropathy	0 [0]		0 [0]	0 [0]		1 [14]

TET, thymic epithelial tumor; irAE, immune-related adverse event.